|
Balance Sheet Cash Flow Statement 675 W. Kendall St. Cambridge, MA 02142 MA Tel. 617-491-9700 Fax 617-621-0431 |
Type: Public
On the web:
http://www.momentapharma.com
Employees:
167
Employee growth: 2.5%
Momenta Pharmaceuticals looks to increase momentum for its drug candidates. The biotech company specializes in engineering complex sugars to improve versions of existing drugs, as well as to discover more-effective new drugs. By analyzing complex sugars, the company provides a more comprehensive picture of the roles sugars play in cell function, disease, and drug action. Momenta has several products in the pipeline, including M-Enoxaparin, a generic version of heparin drug Lovenox from Sanofi-Aventis to treat patients with deep-vein thrombosis and acute coronary syndromes. The company is also developing a generic version of multiple sclerosis treatment Copaxone (marketed by Sanofi-Aventis and Teva).
Key numbers for fiscal year ending December, 2008:
Sales: $14.6M
One year growth: (32.4%)
Net income: ($62.6)M
Officers:
Chairman: James R. (Jim) Sulat
President, CEO, and Director: Craig A. Wheeler
COO: Steven B. Brugger
Competitors:
GlaxoSmithKline
Sanofi-Aventis
Teva Pharmaceuticals
